10/18/2024

Janusmed sex and gender

Janusmed sex and gender – prasugrel besilate

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
A A
A A

Prasugrel

Prasugrel

Class : A

Show all info

Print

Contact us

  1. Efient (prasugrel). Summary of Product Chracteristics. European Medicines Agency (EMA) [updated 2018-12-10, cited 2018-12-21].

  2. Efient (prasugrel). DailyMed [www]. US National Library of Medicine. [updated 2018-03-09, cited 2018-12-21].

  3. Wrishko RE, Ernest CS, Small DS, Li YG, Weerakkody GJ, Riesmeyer JR et al. Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. J Clin Pharmacol. 2009;49:984-98.

  4. Lau ES, Braunwald E, Murphy SA, Wiviott SD, Bonaca MP, Husted S et al. Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials. J Am Coll Cardiol. 2017;69(12):1549-1559.

  5. Lee KK, Welton N, Shah AS, Adamson PD, Dias S, Anand A et al. Differences in relative and absolute effectiveness of oral P2Y12 inhibition in men and women: a meta-analysis and modelling study. Heart. 2018;104(8):657-664.

  6. Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367:1297-309.

  7. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-15.

  8. Almendro-Delia M, Blanco Ponce E, Gomez-Domínguez R, Gonzalez-Matos C, Lobo-Gonzalez M, Caballero-Garcia A et al. Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome An analysis from the 'real world'. J Thromb Thrombolysis. 2015;39(4):499-507.

  9. Widimsky P, Motovska Z, Bolognese L, Dudek D, Hamm C, Tanguay JF et al. Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel. Heart. 2015;101(15):1219-24.

  10. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2018-12-17.]

  1. Efient (prasugrel). Summary of Product Chracteristics. European Medicines Agency (EMA) [updated 2018-12-10, cited 2018-12-21].
  2. Efient (prasugrel). DailyMed [www]. US National Library of Medicine. [updated 2018-03-09, cited 2018-12-21].
  3. Wrishko RE, Ernest CS, Small DS, Li YG, Weerakkody GJ, Riesmeyer JR et al. Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. J Clin Pharmacol. 2009;49:984-98.
  4. Lau ES, Braunwald E, Murphy SA, Wiviott SD, Bonaca MP, Husted S et al. Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials. J Am Coll Cardiol. 2017;69(12):1549-1559.
  5. Lee KK, Welton N, Shah AS, Adamson PD, Dias S, Anand A et al. Differences in relative and absolute effectiveness of oral P2Y12 inhibition in men and women: a meta-analysis and modelling study. Heart. 2018;104(8):657-664.
  6. Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367:1297-309.
  7. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-15.
  8. Almendro-Delia M, Blanco Ponce E, Gomez-Domínguez R, Gonzalez-Matos C, Lobo-Gonzalez M, Caballero-Garcia A et al. Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome An analysis from the 'real world'. J Thromb Thrombolysis. 2015;39(4):499-507.
  9. Widimsky P, Motovska Z, Bolognese L, Dudek D, Hamm C, Tanguay JF et al. Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel. Heart. 2015;101(15):1219-24.
  10. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2018-12-17.]